Michael Okunewitch
Stock Analyst at Maxim Group
(1.27)
# 3,657
Out of 5,055 analysts
29
Total ratings
26.92%
Success rate
-7.23%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.88 | +431.91% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.25 | +380.00% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.28 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $3.00 | +1,066.67% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.40 | +172.73% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $2.66 | +952.63% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.43 | +879.02% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.88 | +59.57% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.19 | +236.13% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.37 | +3,161.76% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.68 | +780.15% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $1.06 | +1,032.08% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.24 | +971.43% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.17 | +729.49% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.22 | +91,116.22% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.25 | +36.99% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.33 | +351.13% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.00 | +525.00% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.98 | +10,114.50% | 1 | Nov 30, 2021 |
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.88
Upside: +431.91%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.25
Upside: +380.00%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.28
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $3.00
Upside: +1,066.67%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.40
Upside: +172.73%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $2.66
Upside: +952.63%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.43
Upside: +879.02%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.88
Upside: +59.57%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.19
Upside: +236.13%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.37
Upside: +3,161.76%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.68
Upside: +780.15%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.06
Upside: +1,032.08%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.24
Upside: +971.43%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.17
Upside: +729.49%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.22
Upside: +91,116.22%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.25
Upside: +36.99%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.33
Upside: +351.13%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.00
Upside: +525.00%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.98
Upside: +10,114.50%